Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis [3]

JAMA

Volumn 296, Issue 18, 2006, Pages 2202-2203

  Callegari, Peter E ^a   Schaible, Thomas F ^a   Boscia, Jerome A ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB;

CLINICAL TRIAL; HUMAN; INFECTION; INFECTION RISK; LETTER; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 33750681621     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.18.2202     Document Type: Letter

References (6)

1. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285.
2. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005;352:351-361.
3. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692-701.
4. Thomas E, Brewster DH, Black RJ, MacFarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer. 2000;88:497-502.
5. US Food and Drug Administration; Center for Drug Evaluation and Research Advisory Committees Meeting documents. March 4, 2003. http://www.fda.gov/ohrms/ dockets/ac/03/transcripts/3930T1.htm. Accessed August 5, 2006.
6. Wolfe F, Michaud K. The risk of lymphoma among persons with rheumatoid arthritis in the United States: no association with anti-TNF therapy [abstract]. European League Against Rheumatism abstract archive. http://www.abstracts2view. com/eular/view.php?nu=EULAR06L_2006SAT0204 Accessed August 5, 2006.